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Abstract
 
Prostaglandin (PG)D
 
2
 
, which has long been implicated in allergic diseases, is currently consid-
ered to elicit its biological actions through the DP receptor (DP). Involvement of DP in the
formation of allergic asthma was recently demonstrated with DP-deficient mice. However,
proinflammatory functions of PGD
 
2
 
 cannot be explained by DP alone. We show here that a
seven-transmembrane receptor, CRTH2, which is preferentially expressed in T helper type 2
(Th2) cells, eosinophils, and basophils in humans, serves as the novel receptor for PGD
 
2
 
. In re-
sponse to PGD
 
2
 
, CRTH2 induces intracellular Ca
 
2
 
1
 
 mobilization and chemotaxis in Th2 cells
in a G
 
a
 
i-dependent manner. In addition, CRTH2, but not DP, mediates PGD
 
2
 
-dependent
cell migration of blood eosinophils and basophils. Thus, PGD
 
2
 
 is likely involved in multiple as-
pects of allergic inflammation through its dual receptor systems, DP and CRTH2.
Key words: prostanoid receptor • G
 
a
 
i-type G protein • T cells • cell migration • allergic 
inﬂammation
 
Introduction
 
Leukocytes migrate from the peripheral blood to sites of in-
flammation through interaction with various cellular and
humoral components such as selectins, integrins, and locally
produced chemoattractants (1, 2). Allergic inflammation is
characterized by selective accumulation of Th2 cells, eo-
sinophils, and basophils, and is often triggered by antigen-
stimulated mast cells (3, 4), although the mechanisms sup-
porting these phenomena are largely unclear.
Recently, we cloned a novel putative chemoattractant
receptor named CRTH2, which is a seven-transmembrane
G protein–coupled receptor structurally related to members
of the 
 
N
 
-formyl peptide receptor (FPR) subfamily (5).
CRTH2 is intriguing in that it is selectively expressed in
Th2 cells, T cytotoxic type 2 cells, eosinophils, and baso-
phils (5–7). Furthermore, CRTH2 can mediate intracellular
 
Ca
 
2
 
1
 
 mobilization in response to a factor(s) released from
activated mast cells, suggesting that CRTH2 may be closely
involved in mast cell–mediated allergic inflammation (6).
In this study, we show that the mast cell–derived
CRTH2 agonist is prostaglandin (PG)D
 
2
 
. This result was
somewhat surprising because PGD
 
2
 
 is generally considered
 
to exert its action via the DP receptor (DP; references
8–10) and because CRTH2 has no significant homology in
amino acid sequence with DP or all other known pros-
tanoid receptors (10). However, in view of the structure, it
may be notable that, like CRTH2, some other lipid medi-
ator receptors such as lipoxin (LX)A
 
4
 
 receptor FPRL1 and
the new leukotriene (LT)B
 
4
 
 receptor BLT2 are also more
closely akin to FPR than the prostanoid receptors (11, 12).
PGD
 
2
 
 is the major prostanoid that is produced by activated
mast cells and thereby has long been implicated in allergic
diseases (10, 13). Most recently, involvement of the DP-
mediated activities of PGD
 
2
 
 in the formation of allergic
asthma has been demonstrated with DP-deficient mice
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(14). However, contribution of DP to the direct effects of
PGD
 
2
 
 on leukocytes, such as induction of eosinophil mi-
gration (15), has not yet been established, raising new ques-
tions such as how these receptors are being used.
Our results show that although CRTH2 functions as a
selective PGD
 
2
 
 receptor as well as DP, it sharply differs
from DP in signaling pathways. Furthermore, CRTH2 but
not DP induces migration of Th2 cells, eosinophils, and
basophils in response to PGD
 
2
 
. Our findings elucidated a
novel function of PGD
 
2
 
 on T cell responses, and CRTH2
is the first receptor that directly and selectively connects a
major lipid mediator of activated mast cells with Th2 cells,
eosinophils, and basophils.
 
Materials and Methods
 
DP Cloning.
 
Human DP cDNA was generated by reverse-
transcription (RT)-PCR using a small intestine poly(A)
 
1
 
 RNA
(CLONTECH Laboratories, Inc.) as a template and the follow-
ing primers: 5
 
9
 
-CTTCCGAAGCCTTCACTCCAGCCCTCT-
GCTCCCG (sense) and 5
 
9
 
-GTTCTTTTCTAGAAAATGT-
GACATATTCCTCAGCTTACC (antisense). The DP cDNA
was cloned into the HindIII-XbaI sites of pRc/CMV (Invitro-
gen), yielding an expression plasmid pRc/DP.
 
Abs.
 
CRTH2-specific rat mAbs BM16 and BM7 were de-
scribed previously (5, 6). Both mAbs were generated by immu-
nizing Wister rats with CRTH2-transfected rat T cell line
TART-1, and their epitopes are still unclear.
 
Cells.
 
Mast cell supernatants were prepared as reported previ-
ously (6). K562 and Jurkat lines were transfected with pRc/B19
(a CRTH2 expression vector; references 5, 6), pRc/DP, or pRc/
CMV and cloned as described (5). Human Th1 and Th2 lines
were generated from the PBMCs of healthy adults by stimulation
with a purified protein derivative of 
 
Mycobacterium tuberculosis
 
 in
the presence of IL-12 and IFN-
 
g
 
 (Th1 condition) or with an ex-
tract of 
 
Dermatophagoides 
 
in the presence of IL-4 and neutralizing
anti–IFN-
 
g
 
 and anti–IL-12 mAbs (Th2 condition), then ex-
panded by IL-2 and used at days 7–14 for examinations as de-
scribed previously (5). In some chemotaxis assays, Th2 cells
highly expressing CRTH2 were enriched by sorting with anti-
CRTH2 mAb BM16 (5) a few days before use. PBMCs and
granulocytes were isolated as described (6).
 
Ca
 
2
 
1
 
 Mobilization.
 
Ca
 
2
 
1
 
 mobilization assays were performed
as described (6). LTC
 
4
 
, LTB
 
4
 
, LXA
 
4
 
, prostanoids, and their syn-
thetic analogues were purchased from Cayman Chemical except
for fluprostenol (Biomol) and PGD
 
2
 
 methyl ester (Sigma-Aldrich).
Thrombin and monocyte chemotactic protein 1 (MCP-1) were
obtained from Sigma-Aldrich and PeproTech, respectively. For
inactivation of G proteins, cells (2.5 
 
3
 
 10
 
6
 
 cells/ml) were incu-
bated with pertussis toxin (PTX; Sigma-Aldrich) or cholera toxin
(CTX; Sigma-Aldrich) at 1 
 
m
 
g/ml for 2 h at 37
 
8
 
C.
 
3
 
H-PGD
 
2
 
 Binding Analysis.
 
Cells washed and suspended in
HBSS containing 10 mM Hepes, pH 7.3 (5 
 
3
 
 10
 
6
 
 cells/100 
 
m
 
l)
were incubated with 1 nM 
 
3
 
H-PGD
 
2
 
 (Amersham Pharmacia
Biotech) for 60 min on ice. Cells were then separated from free
 
3
 
H-PGD
 
2
 
 by centrifugation on RPMI 1640 containing 1 M su-
crose, and radioactivity bound to the cells was measured on a liq-
uid scintillation counter. Nonspecific binding was determined in
the presence of 10 
 
m
 
M cold PGD
 
2
 
.
 
RT-PCR Analysis.
 
Basophils and eosinophils were purified
as described (6). Neutrophils (99% pure as determined by May-
Figure 1. Binding of PGD2 to CRTH2. (A) Expression levels of
CRTH2 as determined by flow cytometry. Cells were stained with bio-
tinylated BM16 (solid line) or control IgG2a (dotted line) as described
(reference 6). (B) CRTH2 mediates Ca21 mobilization by PGD2 and pu-
rified mast cell supernatants. Thrombin was used as an irrelevant stimu-
lant. Arrows indicate the time of stimulant addition. (C) Scatchard plot
analysis for 3H-PGD2 binding to K562/CRTH2 or K562/DP. (D)
CRTH2-mediated binding of 3H-PGD2 is selectively inhibited by BM7.
Cells pretreated with PBS, BM7 (600 mg/ml), or normal rat IgG (600
mg/ml) at room temperature for 20 min were subjected to 3H-PGD2
binding analysis without washing (mean 6 SD, n 5 3). (E) DK-PGD2
and BW245C serve as selective agonists for CRTH2 and DP, respec-
tively, in Ca21 mobilization assay. 
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known mast cell products (13, 16), we found that only
PGD
 
2
 
 can induce Ca
 
2
 
1
 
 mobilization in K562/CRTH2 but
not K562/neo at nanomolar concentrations (Fig. 1 B).
Other mast cell–related and –unrelated inflammatory medi-
ators such as histamine, serotonin, platelet-activating factor,
LTB
 
4
 
, LTC
 
4
 
, regulated upon activation normal T cell ex-
pressed and secreted (RANTES), MCP-1, eotaxin, IL-8,
LXA
 
4
 
, fMLP, C5a, and angiotensin II did not induce any
significant CRTH2-mediated Ca
 
2
 
1
 
 mobilization (5; and
data not shown). Treatment of mast cells with aspirin, a PG
synthesis inhibitor, completely impaired production of the
active component. The active component of the mast cell
supernatants showed an elution profile identical to that of
PGD
 
2
 
 on a reverse phase chromatography using a 
 
m
 
RPC
C2/C18 SC 2.1/10 column (Amersham Pharmacia Bio-
tech) (data not shown). Having once responded to PGD
 
2
 
,
K562/CRTH2 did not show any appreciable Ca
 
2
 
1
 
 mobili-
zation by the mast cell active fraction, and vice versa (cross-
desensitization; Fig. 1 B). These observations demonstrate
that PGD
 
2
 
 is the CRTH2 agonist that is produced by acti-
vated mast cells.
 
Table I.
 
K
 
i
 
 Values of Various Compounds on the Specific Binding 
of 
 
3
 
H-PGD
 
2
 
 to CRTH2 and DP
 
Ligand K562/CRTH2 K562/DP
PGD
 
2
 
61 
 
6
 
 23 45 
 
6
 
 17
DK-PGD
 
2
 
160 
 
6
 
 35
 
.
 
30,000
PGJ
 
2
 
460 
 
6
 
 160 64 
 
6
 
 13
11
 
b-PGF2a 20,000 6 160 1,200 6 470
D12-PGJ2 7,100 6 1,300 5,200 6 1,700
15-deoxy-D12,14-PGJ2 2,300 6 400 .30,000
PGE2 3,100 6 1,100 2,300 6 1,100
PGF2a 2,000 6 780 .30,000
PGA2 .30,000 .30,000
U46619 .30,000 .30,000
BW245C .100,000 50 6 20
PGD2 methyl ester 460 6 120 270 6 46
LTB4 .30,000 .30,000
LXA4 .30,000 .30,000
Inhibitor constant (Ki) values (nM 6 SD, n $ 3) are shown. IC50 values
were determined by the binding of 3H-PGD2 to the indicated cells in
the presence of various concentrations of competing compounds and
converted to Ki values according to the equation Ki 5 IC50/(1 1 [L]/
Kd), where [L] is the concentration of 3H-PGD2 (1 nM) and Kd is its
dissociation constant (taken as 31.3 nM for CRTH2 and 37.7 nM for
DP) (reference 17).
Grünwald Giemsa staining) were purified from granulocytes with
anti-CD16–coated magnetic beads (Miltenyi Biotec). Monocytes
(98% pure), T cells (92% pure), and B cells (91% pure) were iso-
lated from PBMCs with anti-CD14–, anti-CD3–, and anti-
CD19–coupled magnetic beads (Miltenyi Biotec), respectively.
RT-PCR was performed as described previously (5, 6). Primers
for DP were 59-GCAACCTCTATGCGATGCA (sense) and 59-
CAAGGCTCGGAGGTCTTCT (antisense). PCR conditions
were 30 cycles of 948C for 1 min, 558C for 1 min, and 728C for
2 min.
Chemotaxis Assay. This was performed on a 96-well micro-
chemotaxis chamber with a 5-mm-pore filter (Neuroprobe) ac-
cording to the manufacturer’s instructions. In brief, cells (1–2 3
105 cells/50 ml) and test samples (29 ml) prepared in RPMI 1640
containing 10% FCS and 10 mM Hepes, pH 7.3, were applied to
top and bottom wells, respectively, of the chamber. After incuba-
tion at 378C for 1 h, cells in the bottom wells were counted by
flow cytometry. In the case of blood leukocytes, cell types were
determined by Wright’s staining.
Results
CRTH2 Is a Novel Receptor for PGD2. We previously
found that mast cells produce a CRTH2-specific agonist(s)
that can induce Ca21 mobilization in CRTH2-transfected
K562 (K562/CRTH2) but not mock-transfected K562
(K562/neo) (Fig. 1 A; reference 6). In a screening of
Figure 2. Functional discrimination between CRTH2 and DP. (A) DP
but not CRTH2 mediates PGD2-induced cAMP generation. Intracellular
cAMP levels were determined by enzyme-linked immunoassay (mean,
n 5 2; Amersham Pharmacia Biotech). (B) CTX and PTX differentially
affect PGD2-induced (25 nM) Ca21 mobilization in K562/CRTH2 and
K562/DP. (C) Chemotactic responses to agonists (PGD2, DK-PGD2, and
BW245C) are opposite in Jurkat/CRTH2 and Jurkat/DP (mean 6 SD,
n 5 3). Numbers of migrated cells in controls were 727 6 134 (Jurkat/
CRTH2), 439 6 50 (Jurkat/DP), and 661 6 152 (Jurkat/neo).258 Prostaglandin D2 Induces Chemotaxis via CRTH2
The above finding was supported by the experiments us-
ing K562/CRTH2 and DP-transfected K562 (K562/DP;
Fig. 1 A). Both lines exhibited specific binding of 3H-
PGD2 with similar numbers of binding sites per cell and Kd
values of 31.3 and 37.7 nM, respectively, whereas 3H-
PGD2 did not bind to K562/neo (Fig. 1, C and D). A neu-
tralizing CRTH2-specific mAb BM7 selectively inhibited
the binding of 3H-PGD2 to K562/CRTH2 but not K562/
DP, whereas control rat IgG had no effect on this assay
(Fig. 1 D). To establish ligand specificity, binding affinities
to the CRTH2 and DP of PGD2 analogues, major pros-
tanoids, a thromboxane (TX)A2 receptor agonist U46619
(8), a synthetic DP agonist BW245C (8), LTB4, and LXA4
were determined by competitive binding assay (Table I).
The results demonstrate that PGD2 binds to CRTH2 as
well as DP with the highest affinity among various pros-
tanoids. Interestingly, one of the PGD2 metabolites, 13,14-
dihydro-15-keto-PGD2 (DK-PGD2), showed an affinity to
CRTH2 as high as PGD2 to CRTH2, whereas DP showed
at least 600-fold lower affinity to DK-PGD2 than PGD2 as
estimated by the competition assay. In contrast, BW245C
was highly selective for DP.
Consistently, Ca21 mobilization was induced in both
K562/CRTH2 and K562/DP by PGD2, whereas DK-
PGD2 and BW245C were selectively effective in K562/
CRTH2 and K562/DP, respectively, in Ca21 mobilization
assay (Fig. 1 E). No significant Ca21 mobilization was in-
duced in K562/CRTH2 by up to 250 nM PGA2, PGI2,
and TXB2 (data not shown). From these findings, we have
concluded that CRTH2 serves as the novel selective recep-
tor for PGD2. Furthermore, DK-PGD2 and BW245C are
useful reagents that specifically induce CRTH2- and DP-
mediated responses, respectively.
Differences in Signaling Pathways Associated with CRTH2
and DP. To gain insight into functional differences be-
tween CRTH2 and DP, signaling pathways associated with
Figure 3. Selective responses
of Th2, basophils, and eosino-
phils to PGD2. (A) CRTH2 ex-
pression in representative Th1
and Th2 lines. Levels of
CRTH2 expression are pre-
sented as described in the legend
to Fig. 1 A. (B) PGD2 and DK-
PGD2 selectively induce Ca21
mobilization in Th2 cells via
CRTH2. Arrows indicate the
time of addition of the test sam-
ples (black arrows) and 62.5 nM
MCP-1 (white arrows). MCP-1
was used as an irrelevant stimu-
lant. BM7 and rat IgG (each 600
mg/ml) were added 20 min be-
fore the stimulant addition. (C)
Chemotaxis to PGD2 and DK-
PGD2 is selectively induced in
Th2 but not Th1 lines (mean 6
SD, n 5 3). The numbers of mi-
grated cells in controls were
4,015  6  627 (Th1) and 1,374 6
225 (Th2). (D) Chemotaxis to
PGD2 and DK-PGD2 of Th2
cells is inhibited by BM7
(mean  6  SD, n 5 3). Th2 cells
were treated with PBS, BM7, or
normal rat IgG as described in
B before being subjected to
chemotaxis assay. Numbers of
migrated cells in controls were
4,146  6  433 (PBS), 3,283 6 349
(BM7), and 3,246 6 65 (normal
rat IgG). (E) mRNA levels for
CRTH2, DP, and b-actin (in-
ternal control) in peripheral
blood leukocytes and Th lines as
determined by RT-PCR. (F)
Migration of basophils and eo-
sinophils is induced by PGD2
(mean 6 SD, n 5 3). (G) Migra-
tion of eosinophils and basophils
to PGD2 and DK-PGD2 is dose dependent (mean 6 SD, n 5 3). In this experiment, neutrophil (CD161 cell)-depleted leukocyte samples were used. (H)
PGD2-induced migration of basophils and eosinophils is inhibited by BM7 (mean 6 SD, n 5 3). Neutrophil-depleted leukocytes were treated as de-
scribed in D. Asterisks indicate statistical significance with a probability of ,0.01 in Student’s t test.259 Hirai et al. Brief Definitive Report
the two receptors were examined. DP induced cAMP gen-
eration in response to PGD2 as reported previously (Fig. 2
A; reference 9), and DP-mediated Ca21 mobilization was
blocked by CTX but not by PTX as expected (Fig. 2 B). In
contrast, PTX but not CTX inhibited CRTH2-mediated
Ca21 mobilization (Fig. 2 B), and no production of cAMP
was seen by interaction of PGD2 with CRTH2, as expected
(Fig. 2 A). These results indicate that CRTH2 is coupled
with Gai-type G protein and DP with Gas-type protein.
Since many seven-transmembrane Gai-coupled recep-
tors are involved in chemotaxis of leukocytes (1), we then
addressed the issue of whether CRTH2 was responsible for
chemotaxis. CRTH2-transfected Jurkat (Jurkat/CRTH2)
was indeed attracted by PGD2 and DK-PGD2 but not by
BW245C (Fig. 2 C). In sharp contrast, DP-transfected Jur-
kat (Jurkat/DP) was suppressed even in its spontaneous mi-
gration by PGD2 or BW245C. Thus, differential effects of
PGD2 between CRTH2- and DP-expressing cells were
clearly observed, presumably resulting from the difference
in signaling molecules associated with the receptors.
Functional Properties of CRTH2 in Normal Leukocytes.
We next confirmed the above findings with normal leuko-
cytes that naturally express CRTH2. Cultured Th2 but not
Th1 cells showed specific binding of 3H-PGD2, which was
blocked by anti-CRTH2 mAb BM7 (Fig. 3 A, and data
not shown). In response to PGD2 and DK-PGD2, intracel-
lular Ca21 levels in Th2 cells increased (Fig. 3 B) and
chemotactic migration was induced (Fig. 3 C). PGD2 had
no effect on Ca21 mobilization and chemotactic migration
of Th1 cells (Fig. 3, B and C). DP agonist BW245C had no
effect on Ca21 mobilization and chemotactic migration of
Th2 cells (Fig. 3, B and C). The neutralizing anti-CRTH2
mAb BM7 nearly completely inhibited PGD2- and DK-
PGD2–dependent Ca21 mobilization and migration in Th2
cells without affecting their responses to an irrelevant
chemoattractant, MCP-1 (Fig. 3, B and D). Similar results
were obtained in all of five pairs of Th1 and Th2 lines from
five different adults.
In RT-PCR analysis, CRTH2 was expressed highly in
basophils and eosinophils as well as in Th2 lines and weakly
in monocytes, whereas DP was expressed mainly in baso-
phils (Fig. 3 E). When total peripheral blood leukocytes
were tested for chemotactic migration, only basophils and
eosinophils were significantly attracted by PGD2 (Fig. 3 F).
When partially purified (neutrophil-depleted) leukocytes
were tested for the assay, both basophils and eosinophils
more clearly exhibited their migratory responses towards
PGD2 and DK-PGD2 (Fig. 3 G). BW245C, a selective ag-
onist for DP, showed no chemotactic effect on either cell
type (Fig. 3 G). Anti-CRTH2 mAb BM7 but not con-
trol rat IgG blocked the migratory responses to PGD2 of
basophils and eosinophils (Fig. 3 H). Circulating
CRTH21CD41 lymphocytes also showed a tendency to
migrate to PGD2 or DK-PGD2 at z1.5–3-fold higher fre-
quencies than to vehicle or BW245C (data not shown).
The migratory responses of the above three normal cell
types to PGD2 were completely abolished by PTX. A
checkerboard analysis demonstrated that the effect of PGD2
on Th2 cells was mostly chemotactic, whereas on basophils
and eosinophils there was a partly chemokinetic effect as
reported on eosinophils (15). PGD2 is also known to
weakly cross-react with receptors for PGE2, PGF2a, and
TXA2 (18). However, involvement of these receptors in
chemotaxis was ruled out because PGE2, fluprostenol
(a PGF2a receptor–selective agonist; reference 8), and
U46619 (a TXA2 receptor–selective agonist; reference 8)
had no significant chemotactic effect on these three cell
types at nanomolar ranges. Taken together, these results in-
dicate that CRTH2 mediates chemotactic/chemokinetic
signal of PGD2 in a Gai-dependent manner in Th2 cells,
eosinophils, and basophils.
Discussion
Prostanoid receptors have been classified into TX recep-
tor (TP), PGE receptor (EP1, EP2, EP3, and EP4), PGF
receptor (FP), PGI receptor (IP), and PGD receptor (DP;
references 8, 10). In view of the structure, CRTH2 appears
to be unique among members of prostanoid receptors in
that it lacks any consensus amino acid sequence motifs that
are shared by all other known prostanoid receptors (10).
Indeed, a phylogenetic analysis shows that CRTH2 is more
akin in the overall structure to the FPR subfamily members
and receptors for LTs than known prostanoid receptors
(Fig. 4). Furthermore, the chromosomal location of
Figure 4. A phylogenetic tree for human receptors to classical
chemoattractants and major prostanoids. The tree was constructed by the
N-J method using CLUSTAL X software. The sequence of the human
a2B adrenergic receptor was used as an outer group to obtain a root.
Chromosomal locations are shown in parentheses. Accession nos. for the
receptors are (from top to bottom) GenBank/EMBL/DDBJ AF005900,
D38081, L24470, L22647, L27490, L28175, D25418, U19487, Q13258
(GenPept accession no.), AF119711, AF254664, AB008193, AB008193,
AB008535, M62505, L14061, L10820, and M84562. Cys LT, cysteinyl
LT receptor; FPRL, formyl peptide receptor–like receptor.260 Prostaglandin D2 Induces Chemotaxis via CRTH2
CRTH2 (11q12.2) (sequence data available from Gen-
Bank/EMBL/DDBJ under accession no. AC004126) dif-
fers from those of other receptors listed in Fig. 4, suggesting
that CRTH2 might form a novel receptor gene subfamily.
The mechanisms by which CRTH2 binds PGD2 with an
affinity as high as DP remain to be clarified.
PGD2 is currently considered to elicit its biological ac-
tions through DP (8, 10). In fact, well-established PGD2-
induced activities such as vasodilation, relaxation of other
various smooth muscles, and inhibition of platelet aggrega-
tion are apparently mediated by DP because they are also
induced by a DP-specific agonist BW245C (18, 19). How-
ever, several in vivo and ex vivo effects of PGD2 such as an
increase in microvascular permeability, eosinophil infiltra-
tion, and goblet cell depletion are not mimicked by
BW245C (20). Thus, questions on the existence of a
BW245C-insensitive PGD2 receptor subtype(s) has been
repeatedly proposed (20–22). In addition, although DK-
PGD2 is generally thought to be biologically inactive in
many systems, several investigators actually observed its ef-
fects on some PGD2-sensitive tissues (23). Our finding that
CRTH2 is the novel PGD2 receptor functioning differ-
ently from DP may lead to the resolution of such long-
standing questions.
A notable difference between CRTH2 and DP is the
signaling molecules: Gai is used for CRTH2 whereas Gas
is for DP. As shown by many cell types with Gai-coupled
receptors, CRTH2 leads Th2 cell, eosinophil, and basophil
induction of chemotaxis/chemokinesis in response to
PGD2. Consequently, these types of cells may accumulate
at the sites of allergic inflammation (3, 4). Indeed, it was
demonstrated that topical application of PGD2 causes sig-
nificant accumulation of eosinophils in the guinea pig con-
junctiva and the dog trachea (20, 24). In contrast, DP-medi-
ated PGD2 signals caused reduction in spontaneous cell
migration in DP-transfected Jurkat cells and had no effect
on the migration of DP-expressing basophils in our study.
These results suggest that DP-mediated signals may not, in
nature, lead to chemotactic or chemokinetic behavior in
leukocytes. Although PGD2 has been reported to modulate
various activities of neutrophils, we could not detect any
substantial expression of CRTH2 or DP in blood neutro-
phils (25). However, further studies are required to finally
establish the actual involvement of these receptors in the
PGD2-induced modulation of neutrophils.
Although the mechanisms by which DP contributes to
the formation of allergic inflammation remain to be clari-
fied, our results suggest that DP and CRTH2 may be co-
operatively involved in allergic inflammation through dif-
ferent processes. A plausible scenario could be that PGD2 is
largely produced by mast cells upon antigen stimulation,
inducing local vasodilation via DP, which enhances ex-
travasation of blood leukocytes (26), followed by chemo-
tactic migration of Th2 cells, eosinophils, and basophils via
CRTH2 in cooperation with other chemotactic mediators
such as CC chemokines TARC and eotaxin (27, 28).
Thus, CRTH2 may be a new favorable target for allergic
disease therapies. Generation of selective inhibitors for
CRTH2 or CRTH2-deficient mice should help to eluci-
date the physiological and pathophysiological roles of the
CRTH2/PGD2 system and its relative importance in the
host defense mechanisms.
We thank Drs. K. Katayama and F.B. Hoshino (BML) for drawing
the phylogenetic tree.
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